Discounted Cash Flow (DCF) Analysis Levered

ADC Therapeutics SA (ADCT)

$4.89

-0.16 (-3.17%)
All numbers are in Millions, Currency in USD
Stock DCF: -177.92 | 4.89 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.801.142.343.144.225.667.6010.2013.7018.39
Revenue (%)
Operating Cash Flow -74.95-121.36-121.58-168.73-233.38-349.91-469.74-630.60-846.55-1,136.46
Operating Cash Flow (%)
Capital Expenditure -3.16-2.47-2.15-2.81-6.38-8.20-11.01-14.78-19.84-26.63
Capital Expenditure (%)
Free Cash Flow -78.10-123.83-123.73-171.54-239.75-358.11-480.74-645.38-866.39-1,163.09

Weighted Average Cost Of Capital

Share price $ 4.89
Beta 1.108
Diluted Shares Outstanding 65.41
Cost of Debt
Tax Rate 8.54
After-tax Cost of Debt 12.01%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.927
Total Debt 139.70
Total Equity 319.86
Total Capital 459.55
Debt Weighting 30.40
Equity Weighting 69.60
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.801.142.343.144.225.667.6010.2013.7018.39
Operating Cash Flow -74.95-121.36-121.58-168.73-233.38-349.91-469.74-630.60-846.55-1,136.46
Capital Expenditure -3.16-2.47-2.15-2.81-6.38-8.20-11.01-14.78-19.84-26.63
Free Cash Flow -78.10-123.83-123.73-171.54-239.75-358.11-480.74-645.38-866.39-1,163.09
WACC
PV LFCF -188.45-239.75-325.97-398.32-486.74-594.78-726.80
SUM PV LFCF -2,532.60

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.86
Free cash flow (t + 1) -1,186.35
Terminal Value -15,093.50
Present Value of Terminal Value -9,431.74

Intrinsic Value

Enterprise Value -11,964.34
Net Debt -326.85
Equity Value -11,637.50
Shares Outstanding 65.41
Equity Value Per Share -177.92